

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT SHP2 INHIBITOR SITNEPROTAFIB COMBINATION THERAPY DATA PUBLISHED IN ACADEMIC JOURNAL

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that research on the Company’s independently developed SHP2 inhibitor, sitneprotafib (JAB-3312), has been published in *Clinical Cancer Research* (Impact Factor: 10.4). The article details in vitro/in vivo preclinical data and representative cases of patients on the SHP2 inhibitor in combination therapies targeting the RTK/RAS/MAPK pathway and PD-1 blockade therapies.

The study demonstrates that sitneprotafib significantly enhances the anti-tumor activity of the KRAS G12C inhibitor glecirasib in both treatment-naïve and resistant models. Combination of sitneprotafib with MEK inhibitors significantly delayed RTK signaling reactivation and enhanced tumor growth inhibition in KRAS-mutated cancer models. Sitneprotafib-osimertinib combination exhibited great efficacy in osimertinib-resistant non-small cell lung cancer (NSCLC) models. Besides, sitneprotafib enhanced the efficacy of PD-1 blockade therapies by promoting anti-tumor microenvironment.

Currently, the Company is conducting a phase III clinical trial of sitneprotafib in combination with glecirasib, which marks that sitneprotafib is the first globally SHP2 inhibitor to enter phase III clinical trials.

About Sitneprotafib

Sitneprotafib (JAB-3312) is a highly selective SHP2 allosteric inhibitor with best-in-class potential. Jacobio is currently conducting clinical trials of JAB-3312 in monotherapy and combination therapies with glecirasib and other agents in China, the United States and Europe. The phase III study in combination with KRAS G12C inhibitor, glecirasib, has been approved by the Center for Drug Evaluation of the National Medical Products Administration of China in February 2024.

About Glecirasib

Glecirasib (JAB-21822) is a KRAS G12C inhibitor developed by Jacobio. A number of clinical trials of Glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with cetuximab in colorectal cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China.

About Jacobio

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Jacobio's pipeline revolves around novel molecular targets on six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Jacobio's vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that glecirasib (JAB-21822) and sitnepatofib (JAB-3312) will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit www.jacobiopharma.com for more information.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, May 9, 2025

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Dr. Te-li CHEN as non-executive Director, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.